Presentation on theme: "1 LipiGesic Presentation November 2011. 2 Forward Looking Statements Except for the historical information presented, the matters disclosed in this presentation."— Presentation transcript:
1 LipiGesic Presentation November 2011
2 Forward Looking Statements Except for the historical information presented, the matters disclosed in this presentation may include forward-looking statements. These statements represent the companys current judgment on the future and are subject to risk factors and uncertainties that could cause actual results to differ materially. To the extent that there are any statements that can be construed as forward looking, they should be considered in the context of all of our previous releases and federal filings. NOTE: This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any security. There shall be no sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to qualification under securities laws of such state or jurisdiction.
3 Who is PuraMed BioScience ? Engaged in the development and marketing of a line of revolutionary, new, non- prescription medicines targeting major consumer health needs including the treatment of migraine headaches, insomnia and tension-type headaches. PuraMed products comply with all FDA and other regulatory requirements associated with the manufacturing and marketing of its products. PuraMed BioScience, Inc. emphasizes science as the key to success. The Company has engaged leading researchers to conduct human trials as well as In-Vitro studies. On September 20, 2011 PuraMed announced that it has achieved national distribution with a major US retail chain.
4 Intellectual Property Clinical Studies: Although not required, PuraMed is committed to conducting scientific studies to provide independent third party validation to its claims. PuraMed has conducted studies that include: In-Vitro – Test tube or Petri dish studies. In-Vivo – Human trials. Patent – An initial patent on the LipiGesic M product is pending. As a result of the In-Vitro clinical work, PuraMed expects to further bolster its intellectual property by creating a new proprietary ingredient.
5 The Company To build a substantial and profitable business rapidly, beginning with three products developed by its founders, with markets collectively worth well over $6 billion in the U.S. To establish a leadership position in the highly fragmented non-prescription market by introducing a new kind of product line. Our product line consists of effective alternative remedies for common ailments, marketed to the masses. The Company intends to launch its first two retail products then leverage that success to ultimately become a leader in the non-prescription medicine marketplace.
6 Are all effective alternative to both non-prescription & prescription products currently available. Have essentially no competition in the alternative category. Will compete effectively against established standard (non prescription & prescription) products - well prove it. Address predictably recurring ailments. No seasonality. The same consumers continue to suffer. Each customer becomes potentially long-term, substantial, recurring revenue. Product Pipeline: LipiGesic M, LipiGesic H and LipiGesic PM
7 Sublingual delivery is efficient and superior to most other delivery systems. Sublingual Delivery means under the tongue. Faster than pills. The capillaries under the tongue are very close to the surface enabling very fast absorption and action. Avoids the first pass effect. Since the drug is absorbed under the tongue it does not get broken down by the stomach and liver as in the case of pills and liquids that are dosed orally. What is Sublingual Delivery? More Than a Product – Its a Platform
9 PuraMed Market Strategy (Balance of 2011) Commence public relations campaign utilizing our first clinical study. Clinical trials help to overcome consumer and retailer skepticism. Positive clinical results provide third party validation of the products efficacy. The value of the publicity surrounding the release of data can be substantial. Quigley Corporation, the manufacturer of Cold-Eeze®, estimates they received publicity equal to $30 million in free advertising in the year they released the trial results from the Cleveland Clinic. Provide evidence to substantiate product claims to retailers and government agencies.
10 PuraMed Market Strategy (Balance of 2011) Public relations efforts will consist of: Social marketing campaign Medical detailing and sampling Continuing Medical Education (CME) program for doctors and pharmacists Medical conference participation for MDs, DOs, Nurse Practitioners and Physician Assistants Celebrity endorsements
11 PuraMed Marketing Strategy (Balance of 2011) Sales and Advertising Efforts: Resume direct response print advertising campaign Launch LipiGesic M into U.S. retail chain drug (24,000 stores) Finalize and implement celebrity endorsement program
12 Examples of Successful Launches of Naturally Derived Non-Prescription Medications Quigley Corporation (Nasdaq: QGLY): manufacturers of Cold-Eeze® Annual factory sales rose to $70 million within 24 months of launch Market capitalization achieved $300M Matrixx Initiatives (Nasdaq: MTXX): manufacturers of Zicam® Formerly GumTech International, they simply reformatted the zinc-gluconate lozenge into a nasal application and achieved annual sales of over $50 million within 24 months with current annual sales of $96 million Market capitalization achieved $200M
13 LipiGesic M For: Acute relief from migraine headaches and associated symptoms. Fast acting: sublingual. Contains Feverfew (3X) and Ginger (2X).
14 The LipiGesic M Study entitled: A Double-Blind Placebo-Controlled Pilot Study of Sublingual Feverfew and Ginger (LipiGesicM) in the Treatment of Migraine authored by: Roger K Cady, MD, Jerome Goldstein, MD, Robert Nett, MD, Russell Mitchell, Rebecca Browning, has been published as of June 2, 2011 in the journal: Headache: The Journal of Head and Face Pain.
15 Key US Migraine Market Statistics and Facts How bad is the problem? Approximately 50 million people in the US suffer from migraine headaches Migraine headaches are the most costly brain disorder in the US Migraine headaches cost the US economy over $31 billion in Over 2 million children in the US suffer from migraines and there are no prescription medications approved for use in children. Migraine sufferers average 35 attacks per year. That averages out to be 1.65 billion events per year. Migraine headaches last from 4 to 72 hours.
16 Key US Migraine Market Statistics and Facts Who gets migraine headaches? Approximately 18% of women and 6% of men suffer from migraine headaches. The primary age for sufferers is between 18 and 45 years. Migraines generally subside with age, starting after 50. There is a strong genetic link between sufferers. A person who suffers from migraines has a 75% chance of having an immediate family member who also suffers. Less than half of all sufferers have ever been diagnosed by a medical professional. Studies have recently shown that veterans coming home from the wars in Afghanistan and Iraq have twice the occurrence rate versus the general population.
17 Key US Migraine Market Statistics and Facts How effective are current treatments? 57% of migraine sufferers rely exclusively on non-prescription treatments. The lowest cost of the generic form of the leading prescription treatment is $20 per pill and two pills are generally used. Other treatments can cost up to $150 per treatment. The side effects associated with the current triptan treatments can be severe and triptans are contraindicated for many sufferers. The current treatments have a strong association with rebound headaches.
18 HOW DO WE STACK UP VERSUS THE PRESCRIPTION DRUGS?
19 How do we stack up versus the prescription drugs?
20 How do we stack up versus the prescription drugs?
21 How do we stack up versus the prescription drugs?
22 How do we stack up versus the prescription drugs?
23 COMPARISON LipiGesic M vs. 100mg Sumatriptan NUMBER ONE SELLING PRESCRIPTION DRUG
24 Effective LipiGesic M Provides Superior Relief at 2 Hours
26 Effective LipiGesic M Reduces the Rate of Headache Recurrance by Almost 50%
27 Effective In addition to pain relief, LipiGesic M has also been shown to relieve other sympoms commonly associated with migraine headaches including: Pulsating character of the headache Worsening of headache with activity Light sensitivity Sound sensitivity Nausea
28 Less Expensive
29 Less Expensive LipiGesic M will cut the cost of treatment by at least 75%.
30 LipiGesic M Side Effects LipiGesic M provides a side-effect profile similar to placebo. LipiGesic M was well tolerated and no serious adverse events were reported.
31 Triptan Side Effects
32 LipiGesic M Contraindications You should not take LipiGesic M if: You are pregnant or breast feeding If you have a known allergy to any of the ingredients
33 Triptan Contraindications You should not take triptans if you have or have had: Coronary artery disease (with or without angina) A previous heart attack Peripheral vascular disease Uncontrolled high blood pressure Complicated migraines, such as those with temporary weakness in an arm or leg, vertigo, or confusion. You should take with caution if you are: Older than 40, for men Older than 50, for women Currently taking certain antidepressants (talk with your doctor) Or if you: Have diabetes Have a family history of early heart disease or stroke Have high cholesterol Are in menopause Are obese Are pregnant Smoke
34 Easy to Use LipiGesic M is a non-prescription drug, which allows for easy access. LipiGesic M is pre-measured for accurate dosing. LipiGesic M is small and portable. LipiGesic M has no known drug interactions.
35 Summary Comparison of LipiGesic M vs. Sumatriptan 100mg More effective Superior Safety Profile Cuts treatment costs by at least 75% Available without a prescription
36 Tension Over 102 million suffer from chronic and episodic tension-type headache. 1 billion events/year. Majority rely on non prescription. Marginally effective. Significant side effects. No alternative competition. Bests standard products. Recurring, non-seasonal. Unique delivery platform. Migraine Over 50 million suffer. 1 billion + events/yr. Majority rely on non prescription. Marginally effective. Significant side effects. No alternative competition. Bests standard products. Recurring, non-seasonal. Unique delivery platform. Insomnia 70 million suffer. 5 billion events/yr. Majority rely on non- prescription. Marginally effective. Significant side effects. No alternative competition. Bests standard products. Recurring, non-seasonal. Unique delivery platform. Summary
37 Research and Development PuraMed Bioscience, Inc. emphasizes science as the key to success. PuraMed utilizes Hillestad Pharmaceuticals, Inc. a fully licensed and FDA registered prescription and non-prescription drug contract manufacturing facility to produce all of its formulations. PuraMed has currently targeted several key research organizations and leading researchers that it has previously worked with on prior projects.
38 Management Background Russ Mitchell, Chairman and CEO Formerly served as an Officer and/or Director of several publicly traded companies. Pioneer in establishing the marketing value of clinical trials to demonstrate the effectiveness of OTC remedies. 29 years of sales and marketing experience, including 19 years of national level management, sales, marketing and new product development in the drug and nutritional supplement industry. Experienced in the formulation and manufacturing of prescription drugs, OTC drugs and nutritional supplements in tablet, capsule, powder and liquid form. Served over 48,000 retail locations nationwide.
39 Management Background (cont.) Arthur Pirrone, Vice President of Sales Over 30 years experience in the sales and marketing of Health & Beauty Aid products. Well known industry expert and respected in the mass market field. Prior experience includes sales, marketing, training and managerial positions with three Fortune 500 companies, as well as top level management position with several entrepreneurial OTC/HBC organizations. Extensive experience in launching new products, expanding distribution of currently stocked brands and maximizing the profitability of each product line. He has hired, trained and managed both direct and broker/rep national sales forces.
40 Management Background (cont.) Jim Higgins, COO and CFO Formerly served as an Officer and/or Director of several publicly traded companies. Served as Executive VP of Mitchell Health Marketing Alliance, a sales and marketing firm with additional expertise in product development, manufacturing, retail distribution and logistics of OTC drugs and nutritional supplements. Spent 15 years with the AC Nielsen Co., where he was responsible for managing accounts with some of the most prominent consumer product companies in America, including Kraft Foods and Unilevers – Good Humor Breyers Ice Cream.
41 Migraine Market Projections
42 Investment Summary New investor summary PuraMed BioScience has achieved all of the key milestones it set forth for its launch of LipiGesic M into the US market as a credible effective treatment for migraine headaches. The company has developed a migraine treatment that outperforms the number one selling prescription treatment in the relief of pain and associated symptoms, safety, ease of use, ease of access(no Rx needed) while cutting treatment costs by at least 75%. On January 3, 2011 the company announced that it had completed its clinical study on LipiGesic M. This study was conducted by three nationally recognized headache specialists including Roger Cady MD, Jerome Goldstein MD and Robert Nett MD RPh. On June 2, 2011 the company announced that the clinical study proving LipiGesic M as a highly effective treatment for migraine headaches was published in the top tier medical journal Headache. On September 20, 2011 the company announced that it has achieved national distribution with a top US retailer (Walgreens).
43 Contact Info PuraMed BioScience, Inc. Russell Mitchell, Chairman and CEO Investor Relations: Investor Awareness, Inc. Tony Schor or James Foy, Website: Media: North Shore Public Relations, Inc. Renae Placinski, Website: